Celanese Reports Significant Full-Year Loss and Goodwill Impairment Amidst Challenging Market
CE sits 65% above its 52-week low of $35.13 on elevated volume (2.3× avg).
Summary
Celanese reported a substantial full-year 2025 GAAP loss of $10.44 per share, including a $1.1 billion goodwill impairment, and provided cautious Q1 2026 guidance, reflecting ongoing market challenges.
Key Events · Earnings and Guidance · CE
-
Full-Year 2025 Performance
Reported a U.S. GAAP diluted loss per share of $10.44 and adjusted earnings per share of $3.98, with net sales decreasing 7% to $9.5 billion.
-
Significant Goodwill Impairment
Included a $1.1 billion goodwill impairment charge, primarily impacting the Engineered Materials segment, contributing to the substantial GAAP loss.
-
Q4 2025 Results
Posted U.S. GAAP diluted EPS of $0.23 and adjusted EPS of $0.67, with net sales of $2.2 billion, representing a 9% sequential decline.
-
Q1 2026 Guidance
Anticipates adjusted earnings per share between $0.70 and $0.85, indicating continued modest demand and a slight sequential improvement from Q4 2025.
Analysis · CE · Industrial Applications And Services
Celanese Corporation reported a substantial full-year 2025 GAAP diluted loss per share of $10.44, primarily driven by a significant $1.1 billion goodwill impairment charge. Adjusted earnings per share also saw a considerable decline to $3.98 for the year, reflecting a 7% decrease in net sales due to lower prices and volumes. Fourth-quarter results continued this trend with sequential and year-over-year declines in sales and adjusted EPS. The company's Q1 2026 adjusted EPS guidance of $0.70-$0.85 suggests ongoing demand challenges, while the full-year 2026 free cash flow target is slightly below 2025 levels. The impairment charge indicates a re-evaluation of asset values and highlights the difficult operating environment.
At the time of this filing, CE was trading at $57.90 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $35.13 to $70.51. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.